Investieren in die Zukunft von morgen.

... ich möchte mir nämlich noch  ein paar "günstig" ins Depot packen  ;-))))  

in meinem Depot.Der Hype kommt .Die Ampeln stehen überall auf grün.  

einen schönen guten morgen :-)))

lg bee :-)

 

Soweit ich das verstanden habe, kommen $1,500,000 von einem privaten Investor.

http://www.microcapmarkets.com/...83&market=OTCBB&ticker=CBAI  

 

richtig.
Da wurde der Vertrag geschlossen.

Das 8-K Filling ist datiert am 11.01.10 und das 8-K/A ist auf den 12.01, Veröffentlichung ebenfalls am 12.  

kriegt der investor dafür neue aktien? bzw wie viel...  

Nasdaq OTC BB 5.000     0,0001 $     0,0167 $    5.000     16,6 T%

von Heute!!!

wenn bald eine News zu den Abschlüssen der Verhandlungen mit den Firmen in verschiedensten Ländern von Europa veröffentlicht wird ?
Da die PR-Abteilung bisher hervorragend gearbeitet hat, habe ich irgendwie "im Gefühl" als wenn vor der Eröffnung noch ein Knaller ´rausgehauen´wird und dann ...
Der ´Knaller´muss nicht unbedingt  mit Europa zu tun haben, aber das muss ja auch noch irgendwann kommen - wenn es denn geklappt hat. ;-)

Tippe (hoffe) schon heute wieder mit grün.

Glück auf!  

Was willst du damit sagen? Sprich dich doch aus!

Sollen wir alle wacker verkaufen - oder was ?

Glück auf!  

Will nichts damit sagen.
Bin nur erstaunt was hier alles möglich ist.
Wird schon nicht so schlimm werden.

Völlig uninteressant,das wird nur falsch angezeigt!
Schauen wir nochmal um 15 Uhr,da siehts bestimmt ganz anders aus!

Nasdaq OTC BB 5.000 0,0162 $   0,0172 $   5.000 6,17% 13:35:36

Na dann haben wir noch mal Glück gehabt. LOL

Cord Blood America: A Bet on Stem Cell Research
Written on Tuesday, January 12th, 2010 by Rick Telfur



Cord Blood America Inc. (OTC:CBAI) may not be your average business model for a medical stock, but growth in stem cell research and the company’s ambitious expansion plans make it worth a second look!


Cord Blood America Inc. (CBAI) collects, tests, processes and preserves umbilical cord blood for use in future stem cell therapy. As of October 2009, the company offers blood banking services to all 50 states and realizes a one-time enrollment fee as well as annually recurring storage and maintenance fees.

The company’s business model is based on the uniform belief that stem cells will play a key role in fighting disease in the future. And umbilical cords contain a rich store of stem cells that have already been used to treat 75 diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies.

Recently, the company’s move to de-emphasize its legacy radio and advertising business, along with the overall sluggish economy, has led to a sharp drop in revenues and net income. However, many investors believe that recent growth initiatives, geographic diversification and a recovering economy will help drive improved results in subsequent quarters.

A Solid Growth Strategy for 2010

Cord Blood America recently completed investor-friendly capital-raising over the past 18 months, in the amount of $16.8 million. The new capital comes in the form of lines of credit, meaning that it does not dilute shareholder value nor create any immediate balance sheet obligations. The company plans to use the capital for several initiatives:

“We intend to continue our organic growth in this business through continued improvement of internal processes, continued improvement and expansion of our relationships with health insurance providers, and through continuing efforts to leverage those relationships in the pregnancy programs with those providers.

“We also plan to build additional sales channels through obstetrics and gynecological practices and other healthcare professionals, hospitals and other health care influencers. We also hope to leverage our growth through mergers and/or acquisitions of other stem cell preservation companies.”

Source: 10-Q Filing from the SEC

The company noted in a recent press release that the funds themselves would be used to grow through acquisitions. While this can be a somewhat risky way to leverage up and expand, it can pay big dividends to investors if the business takes off and stem cells become a necessity in everyday life to treat diseases.

Stem Cell Research is a Near-term Catalyst

Stem cell research has begun to gain momentum after the Obama administration reinstituted government funding for the sector. In fact, stem cells have already been shown to be effective in treating mice, but the Food and Drug Administration has been a key roadblock, requiring expensive safety testing before human trials can be conducted.

Until now, this has meant spending a lot of money that simply wasn’t available for such a risky technology that was unproven. But with Obama’s repeal of the anti-stem cell research regulation, new funding is flowing into the sector that should fast-track these studies and stem cell research itself, thereby making Cord Blood America’s storage more necessary to the public.

One great example of this growth in funding was from the California Institute for Regenerative Medicine, which recently provided $18 million in state funding for stem cell research thanks to the state’s Proposition 71. Projects like this are helping to fill a void between being too commercial for federal funds and too risky for private investors.

Demand is also clearly seen in the public, with a growing number of people that even make a pilgrimage to China in order to receive stem cell injections that can help treat disease. Meanwhile, Canada already allows a few safe and proven stem cell therapies to be used to treat blood disorders like leukemia with bone marrow transplants and immune disorders.

The Takeaway…

¦Cord Blood America is positioning itself to be a leader in umbilical cord blood preservation with a strategy to grow organically and through acquisitions.
¦A revival in stem cell research and strong consumer demand could provide a key catalyst for the company moving forward.
¦Despite the upside, Cord Blood America remains a very risky investment given the controversy and limited research surrounding stem cell treatments.  

heute wirdein geiler grüner Tag :)

 

durch reibung entsteht hitze wie bekannt meine Händee brennen schon yeahhhh

 

 

habe ich das gefühl  

 

immer etwas beunruhigt ist die entwicklung von märz bis september 09
nicht dass das hier identisch abläuft und wir bald wieder bei 0,003 etc sind  

gerade 100 k zu 0,01 aufgestockt ! Thanks  

 

gleich ein ;-)
 

was ich mich jetzt frage, ob die laboreröffnung nächste woche freitag überhaupt bis dato noch auswirkungen auf den kurs haben wird?!  

wird größer den je